-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Arbidol Re-included in the New Edition of the COVID-19 Diagnosis and Treatment Protocol
Category:
发布时间：2020-08-20
Previously, the team led by Li Lanjuan, an academician of the Chinese Academy of Engineering and a member of the National Health Commission’s High-Level Expert Group, announced in Wuhan their latest research findings on the treatment of pneumonia caused by novel coronavirus infection, which confirmed the clinical efficacy of arbidol. On February 19, arbidol was included for the first time in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6). On March 4, arbidol was once again incorporated into the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
According to available information, Arbidol is an antiviral agent primarily indicated for the treatment of upper respiratory tract infections caused by influenza A and B viruses, among others, and exhibits broad-spectrum antiviral activity. Its mechanism of action involves inhibiting the fusion of the viral envelope with host cell membranes, thereby blocking the initial step of viral entry. In addition, Arbidol can induce the production of endogenous interferon, which not only suppresses viral replication but also modulates and enhances the host’s immune response, conferring multiple mechanisms of antiviral efficacy. In 2019, it was included in the National Health Commission’s list of clinically recommended antiviral agents for influenza.
Shijiazhuang Sihua Pharmaceutical is one of the earliest domestic pharmaceutical companies to develop arbidol, and its arbidol hydrochloride capsules have played a positive role in COVID-19 prevention and control since the outbreak began, being included on the drug reserve lists for COVID-19 prevention and control in numerous provinces and cities.
During the COVID-19 pandemic, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. conscientiously fulfilled its social responsibility by making every effort to ensure the supply of Arbidol Hydrochloride Capsules, successfully completing both national allocation and provincial-level procurement and stockpiling tasks. The company received high praise from the Medical Supplies Guarantee Group of the Joint Prevention and Control Mechanism under the State Council for Responding to the Novel Coronavirus Pneumonia Epidemic, the Party Committee and Government of the Shennongjia Forestry District, as well as relevant medical institutions and pharmaceutical trading enterprises.
At present, the global COVID-19 pandemic continues to spread. In response to the evolving epidemic situation abroad, Shijiazhuang Sihua Pharmaceutical has stepped up to its social responsibility: while successfully ensuring the domestic supply of abidor hydrochloride capsules, the company has also mobilized production capacity to meet international market demand and support the global fight against the pandemic. To date, Shijiazhuang Sihua Pharmaceutical has reached export intentions for abidor hydrochloride capsules and other anti-pandemic drugs with more than 10 international clients, and some shipments have already been dispatched.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code